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Abstract
Background: The aim of the study was to evaluate plasma natriuretic peptides (NPs): atrial
natriuretic peptide (ANP) and brain natriuretic peptide (BNP) concentrations in patients
with paroxysmal, persistent and permanent atrial fibrillation (AF).
Methods and results: The study groups consisted of 23 patients with paroxysmal AF,
42 patients with permanent AF and 77 patients with persistent AF with normal left ventricular
function. The mean ANP level was increased in AF patients in the paroxysmal, persistent and
permanent groups: 249 ± 88.3 pg/mL; 258 ± 89.7 pg/mL; 208 ± 76.7 pg/mL, respectively, vs.
67 ± 21.2 pg/mL in the control subjects (p < 0.001). The mean BNP level was increased in
AF patients in the paroxysmal, persistent and permanent groups: 99.6 ± 29.8 pg/mL; 82.3 ±
± 33 pg/mL; 95.6 ± 46.4 pg/mL, respectively, vs. 37.5 ± 13 pg/mL in the control group.
Multivariate logistic regression analysis revealed a positive correlation between ANP levels,
maximal left atrial volume, heart rate and New York Heart Association (NYHA) classifica-
tion, in the persistent AF patients. A positive correlation between plasma BNP levels and heart
failure stage according to NYHA classification in this group was found. Baseline ANP con-
centrations were positively correlated with baseline BNP concentrations in AF patients.
Conclusions: Plasma NPs levels are increased in patients with paroxysmal, persistent and
permanent AF and normal left ventricle function, and positively correlated with left atrial
volume, heart rate and heart failure stage according to NYHA classification. Neurohormonal
assessment does not distinguish the type of arrhythmia. (Cardiol J 2008; 15: 525–529)
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Introduction
Atrial fibrillation (AF), because of its clinical
importance, which lies in the associated morbidity,
mortality, economic impact on society and the lack
of satisfactory management approaches, is the sub-
ject of active clinical and research efforts. The stu-
dies on neurohormonal remodeling in patients with
AF are becoming increasingly important. The re-
sults might influence the management of these pa-
tients. Natriuretic peptides (NPs) have been shown
to be very powerful prognostic markers in epide-
miological and clinical trials in heart failure, acute
coronary syndromes and pulmonary diseases or
in the general population [1]. The two most promi-
sing NPs to measure in these regards are atrial
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natriuretic peptide (ANP) and brain natriuretic pep-
tide (BNP) or their amino (N–) terminal tails [2].
The aim of the study was to evaluate plasma
NPs: ANP and BNP concentrations in consecutive
patients with paroxysmal, persistent and permanent
AF admitted to the Cardiology Department, com-
pared to subjects with sinus rhythm.
Methods
A prospective study enrolled consecutive sub-
jects aged 40–75 years, with paroxysmal AF with
duration < 48 hours, persistent with duration time
> 48 hours and £ 12 months or permanent AF; with
underlying hypertension, coronary artery disease
or lone AF, with normal left ventricular function
[ejection fraction (EF) ≥ 50%], between April 2002
and January 2004. The control group comprised of
20 subjects with similar concomitant diseases but
with normal sinus rhythm without history of AF.
The reference value of plasma NP levels was obta-
ined from 21 healthy adult volunteers. Exclusion
criteria were: congenital heart disease, rheumatic
valve disease, uncontrolled hypertension, uncon-
trolled ventricular rate (≥ 100 beats/min), symptoms
of heart failure > II according to New York Heart
Association (NYHA) classification, considerable di-
latation of heart cavities (left atrial anteroposterior
dimension > 60 mm, left ventricle end-diastolic dia-
meter > 65 mm, and/or left ventricular end-systo-
lic diameter > 45 mm), EF of left ventricle in echo-
cardiography < 50%, acute coronary syndrome
within 6 weeks, renal, liver or respiratory failure
or malignancy. Blood samples for ANP and BNP as-
sessment were obtained from the antecubital vein
with the patient in the supine position after a re-
sting period of 30 min. Mean and maximum heart
rate were assessed from 24-hour ECG monitoring.
All specimens were collected in tubes containing
EDTA (ethylenediaminetetraacetic acid) 1.5 g/L,
and a protease inhibitor aprotinin (Traskolan, Jelfa,
Jelenia Góra, Poland) 500 KIU/mL. The plasma was
separated by centrifugation (at 2500 rpm) for 20 min
at 4°C and stored at –70°C until measurement. The
plasma concentrations of ANP and BNP were me-
asured by radioimmunoassay methods (Peninsula
Laboratories Inc., San Carlos, CA, USA). Values
of ANP and BNP were expressed as pg/mL. The in-
tra- and interassay coefficients of variation were, for
ANP: 7.1% and 11.1%, and for BNP: 5.6% and 9.0%,
consecutively. Data are given as mean ± standard
deviation in cases of normal distribution, whereas
median values with ranges are given for non-normally
distributed variables. The clinical characteristics
of the 3 patient groups were compared using the
c2 test for categorical variables, and the unpaired
t test for continuous variables. In cases of non-nor-
mally distributed variables, differences were te-
sted using Wilcoxon’s 2-sample test. Multivariate
logistic regression analysis was performed to find
correlations between plasma NP levels and some
clinical and echocardiographic parameters. Stati-
stical significance was defined as p < 0.05. All
analyses were performed using the Statistical
Analysis System program (SAS Institute, Cary,
NC) version 8.2.
The study was explained to each patient and
written consent was obtained. The study protocol
was approved by the Local Ethical Committee.
Results
Twenty-three patients with paroxysmal AF,
42 patients with permanent AF and 77 patients with
persistent AF were examined. The characteristics
of the study groups are presented in Table 1. The
mean baseline plasma ANP level in healthy volun-
teers (12 male, 9 female), aged 56 ± 10 years, was
29.7 ± 7.7 pg/mL with 95% confidence interval
(CI, 21.17; 33.16 pg/mL), and BNP level was 21.6 ±
± 5.2 pg/mL with 95% CI (19.56; 24.63 pg/mL). The
mean ANP level was increased in AF patients in the
paroxysmal, persistent and permanent groups: 249 ±
± 88.3 pg/mL; 258 ± 89.7 pg/mL; 208 ± 76.7 pg/mL,
respectively, vs. 67 ± 21.2 pg/mL in the control
group (p < 0.001) (Fig. 1). A trend was found for
lower levels of ANP in the permanent group com-
pared with the persistent AF group. The mean BNP
level was increased in AF patients in the paroxy-
smal, persistent and permanent groups: 99.6 ±
± 29.8 pg/mL; 82.3 ± 33 pg/mL; 95.6 ± 46.4 pg/mL,
respectively, vs. 37.5 ± 13 pg/mL in the control gro-
up (p < 0.001) (Fig. 2). Multivariate logistic regres-
sion analysis revealed a positive correlation between
ANP levels and maximal left atrial volume (LPvol)
(p = 0.0001), maximal heart rate (HRmax) (p = 0.0036)
and symptoms of heart failure according to NYHA
classification (p < 0.0001) in the persistent AF pa-
tients (Table 2). A regression function for plasma
ANP was calculated as follows: ANP = –259.8 +
+ 1.43 × LPvol + 81.45 × NYHA class + 2.17 ×
× HRmax.
The model of linear regression was statistical-
ly significant for r2 = 0.55 (r = ÷r2), p < 0.0001.
A positive correlation between plasma BNP levels
and heart failure stage according to NYHA classifi-
cation in the AF patients was found (p < 0.0001)
(Table 2). A regression function for plasma ANP was
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Table 1. Baseline characteristics and natriuretic peptide concentrations in study groups (mean ± SD).
Data Paroxysmal AF Persistent AF Permanent AF Control p##
(n = 23) (n = 77)  (n = 42) group
(n = 20)
Age (years) 57.6±10.5 59.8±9.27 64.3±7.7 61.8±8.1 NS (0.077)
Gender: male/female (%) 15/8 (65) 52/25 (68) 27/15 (64) 13/7 (65) NS
Duration of AF (hours, days, 14 101 46,7
months) median/range (2–48)* (2–392)** (11–66)***
Predominant cardiac diagnosis
Coronary artery disease (%) 6 (26) 16 (21) 11 (26) 7 (35) NS# (0.22)
History of hypertension (%) 11 (48) 51 (66) 26 (62) 13 (65) NS#
No heart disease (lone AF) (%) 6 (26) 10 (13) 5 (12) – NS#
Heart rate mean [beats/min] 90.1±8.5 77.2±9 81±8.1 71±7 < 0.0011
Systolic blood pressure [mm Hg)] 110±15 123±16 131±15 129±15 < 0.0012
Heart failure according NS#
to NYHA class (%) (0.31)
I 8 (35) 23 (30) 12 (60) 12 (60)
II 15 (65) 42 (54) 8 (40) 8 (40)
No symptoms of heart failure (%)  – 12 (16)  – –
Echocardiographic findings
Size of left atrium antero-posterior [mm]  46.8±3.7  46.6±4  47.5±5.3  45.2±2.7  NS (0.2)
Left atrial volume [mL] 87.1±22.5 88.2±20 110.0±35.6 78.3±11.6 < 0.00013
LVEDD [mm] 49.8±5.7 50.8±6 52.3±5.8 51.7±3.5 NS (0.3)
LVESD [mm] 34.1±5.6 35.2±6 36.4±6.9 32.4±3 NS (0.09)
LVEF (%) 60.3±7 58.1±6 56.1±6.9 61.8±3 0.0034
Baseline ANP [pg/mL] 249.0±88.3 257.7±89.7 207.5±76.7 67±21.2 < 0.0015
Baseline BNP [pg/mL] 99.6±29.8 82,3±33 95.6±46.4 37.5±13 < 0.0016
AF — atrial fibrillation; LVEDD — left ventricular end-diastolic diameter; LVESD — left ventricular end-systolic diameter; LVEF — left ventricular ejection
fraction; NYHA — New York Heart Association; ANP — atrial natriuretic peptide; BNP — brain natriuretic peptide; *hours; **days; ***months; #groups
were compared with the c2 test; ##The clinical characteristics of the two patient groups were compared with the unpaired t test but comparison of
4 groups was performed using analysis of variance; 1Significant differences were noticed between persistent, permanent AF or control group and
paroxysmal AF group; 2Significant differences were noticed between all groups except persistent and permanent AF; 3Significant differences were
noticed between the permanent AF group and the other groups; 4Significant differences were noticed between permanent and paroxysmal AF, and
between permanent AF and control group; 5Significant differences were noticed between the control group and patients of paroxysmal, persistent
and permanent AF groups; 6Significant differences were noticed between the control group and patients of paroxysmal, persistent and permanent
AF groups
Figure 2. Plasma brain natriuretic peptide (BNP) levels
in study groups and in the control group.
Figure 1. Plasma atrial natriuretic peptide (ANP) levels
in study groups and in the control group.
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calculated as follows: BNP = 36.12 + 33.25 ×
× NYHA class.
The model of linear regression was statistical-
ly significant for r2 = 0.56 and p < 0.001. Plasma
ANP concentrations were positively correlated with
baseline BNP concentrations in all AF groups with
coefficient Pearson linear correlation in paroxysmal
AF r = 0.65 (p = 0.008), in persistent AF r = 0.59
(p < 0.0001), and in permanent AF r = 0.43
(p = 0.0007).
Discussion
In our study we demonstrated that AF in pa-
tients with normal ventricular function influences
NP secretion as much in paroxysmal and persistent
arrhythmia as in permanent types of arrhythmia. In
our previous studies we proved the increase of ANP
in persistent AF and BNP in paroxysmal type of
arrhythmia [3, 4]. This is the first study to evaluate
both plasma ANP and BNP peptides in paroxysmal,
persistent and permanent AF patients with normal
left ventricle function. The general function of NP
is to modulate cardiac preload and afterload by the-
ir effect on water and electrocyte balance and car-
diovascular growth. NPs also have vascular smooth
muscle relaxing actions [5, 6]. The expression of
both ANP and BNP is modulated by many triggers,
such as wall stress, intracavity pressure loading of
the circulation, and increases in atrium and ventricle
dimensions in conditions of chronic pressure or
volume overload. The plasma NP levels are known
to be indicators of left ventricle dysfunction. The
NP measurements have been used in the diagnosis
of heart failure, being positively correlated to the
severity of heart disease according to NYHA clas-
sification. However, the role of NP in patients with
AF and preserved cardiac function has not been well
determined. In the study both ANP and BNP levels
were positively correlated with NYHA class in pa-
tients with persistent and permanent AF. Although
ventricles were supposed to be the main source of
BNP, the biochemical evidence supports a predo-
minantly atrial source of NPs [5]. We found a posi-
tive correlation between plasma ANP concentration
and left atrial volume and heart rate. The growing
frequency of atrial depolarization influences the
increase in the peptide concentrations during AF.
It has been documented that rapid heart rate sti-
mulates ANP release regardless of cardiac wall ten-
sion. In addition, released ANP can be stored in the
cardiomyocyte granules localised in pacemaker and
conduction system cells [7]. The increases in ANP
and BNP secretion may be related to the sympa-
thetic nervous system, as well as to the renin-an-
giotensin-aldosterone system. In the study, a clo-
se relation was observed between atrial volumes
and ANP concentrations. We reported that plasma
ANP release after successful cardioversion might
be due to the recovery of left atrial mechanical func-
tion [8]. It confirms hypotheses that the recovery
of atrial mechanical function plays a role in ANP
secretion. We previously also showed that prolon-
ged duration of AF and NP activation leads to exhau-
stion of the NP regulatory system, and that a decre-
ase in the secretion reserve of atrial cardiomyocy-
tes, documented during exercise testing, predicts
cardioversion failure or AF recurrence [9, 10].
It seems that ANP in AF is a protective but time-
limited system due to inherent destructive time-de-
pendent structural and functional effects of AF. It
is still under debate whether BNP is independen-
tly influenced by AF. In Rossi et al’s study BNP,
unlike ANP, was not affected by the presence of AF
in patients with left ventricular dysfunction, orga-
nic mitral regurgitation or lone AF [11]. Unlike the
Table 2. The comparison of plasma ANP and BNP levels in study groups depending on symptoms of
heart failure according to NYHA classification (mean ±SD).
Study group Plasma ANP levels [pg/mL] Plasma BNP levels [pg/mL]
No I NYHA II NYHA p No I NYHA II NYHA p
symptoms symptoms
Paroxysmal AF 209±95 270±80 NS (0.12) 68±10 116±22 < 0.0001
Persistent AF 149±41 227±74 305±72 < 0.00011 41±8 64±8 104±28 < 0,00012
Permanent AF 110±23 196±63 244±73 0.00073 49±11 93±43 111±47 0.02284
Control group 66±20 68±24 NS (0.87) 29±3 50±12 0.0032
AF — atrial fibrillation; NYHA — New York Heart Association; ANP — atrial natriuretic peptide; BNP — brain natriuretic peptide; *The plasma ANP
and BNP levels of the two patient groups were compared with the unpaired t test but comparison of 3 groups was performed using analysis of variance;
1Significant differences were noticed between all groups; 2Significant differences were noticed between all groups; 3Significant differences were noticed
between the group without symptoms of heart failure and groups in classes I and II of heart failure according to NYHA classification; 4Significant dif-
ferences were noticed between the group without symptoms of heart failure and groups in class II of heart failure according to NYHA classification
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Rossi study, other authors demonstrated that AF
affects BNP secretion in patients with persistent
and paroxysmal types of arrhythmia and with nor-
mal left ventricular function [12–14]. The presen-
ce of AF should be taken into consideration when
interpreting plasma NP concentrations. The pro-
gnostic implication of increased BNP concentra-
tions in patients with AF seems to be different from
enhanced response of ANP to increased workload.
In a prospective study of a community of 3346 sub-
jects without heart failure, NP was associated with
the risk of AF (values > 80th percentile were asso-
ciated with a doubling of other risks) after adjust-
ment for traditional risk factors [15]. Further stu-
dies are required to determine the exact progno-
stic value of NP assays in patients with such highly
heterogeneous conditions as AF and to validate the
findings discussed above.
Conclusions
Plasma NP levels are increased in patients with
paroxysmal, persistent and permanent AF and nor-
mal left ventricle function, and positively correla-
ted with left atrial volume, heart rate and heart
failure stage according to NYHA classification. The
neurohormonal assessment does not distinguish the
type of arrhythmia.
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